Background: Androgens play a role in the development of both androgenic alopecia, commonly known as male pattern baldness, and prostate cancer. We set out to study if early-onset androgenic alopecia was associated with an increased risk of prostate cancer later in life.
introduction
Androgenic alopecia, commonly known as male pattern baldness, is a common disorder affecting almost 50% of men throughout their lifetime. It is usually seen in older men, but it may arise precociously. A link between male pattern baldness and androgens has previously been documented [1] [2] [3] . Androgens also play a role in the development and growth of prostate cancer. Finasteride, a type II 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone, is used for the treatment of androgenic alopecia and has been shown to decrease the incidence of prostate cancer [4, 5] .
Despite this, a direct link between male pattern baldness and prostate cancer has not been consistently shown [6] [7] [8] [9] [10] [11] [12] . Authors have suggested that inconsistencies in results may be due to differences in the patterns of hair loss and in the time frame of development of androgenic alopecia. Alopecia occurring in younger males (before the age of 30), as well as hair loss implicating the vertex, may be a precursor to developing prostate cancer later in life [9, 10, 13] . To help answer these questions, we undertook a case-control study to evaluate the impact of early-onset androgenic alopecia on the incidence of prostate cancer.
patients and methods
Case subjects were all successive patients with a diagnosis of prostate cancer seen in a radiation oncology follow-up clinic at one of the participating institutions in France (Hô pital Européen Georges Pompidou, Paris; Institut Curie, Paris; and Institut Claudius Regaud, Toulouse). Controls were chosen from the same hospital databases and were patients with no history of prostate cancer or hormonal pathologies. Cases and controls groups were frequency matched according to date of birth.
Starting in September 2004, after approval by respective hospitals' ethics boards, and for a period of 28 months, participants were contacted by mail and asked to complete a short questionnaire. All subjects were asked if there was a personal history of prostate cancer (yes/no checkbox), as well as a history of balding or prostate cancer in the father. Participants then scored their balding pattern at ages 20, 30 and 40, according to a set of four pictures (Figure 1) , adapted from the Hamilton-Norwood scale [11, 14] . The first picture (stage I) represented no balding. The second picture (stage II) showed frontal hair loss, while the third picture (stage III) showed vertex hair loss. The fourth picture (stage IV) represented both concurrent frontal and vertex balding. This type of self-reporting questionnaire has been validated for retrospective assessment of alopecia [15, 16] .
Physicians of all respondents were asked to complete a separate questionnaire, confirming the presence or not of a history of prostate original article 
statistical analysis
Sample size was calculated based on computer simulation using prevalence found in previous studies of early-onset alopecia at 40 years of age. The power was to be 77% with an accrual of 1500 cases. Data was compiled at a single institution (Institut Curie). Ages between cases and controls were compared using the Student's t-test. We used a chi-square test to analyze the relationship between alopecia at various ages (ages 20, 30 and 40) and the prevalence of prostate cancer, as well as the relationship with aggressive prostate cancers (T3-4 tumors, PSA > 20, Gleason score ‡7). Odd ratios and confidence intervals (CIs) were obtained from 2 · 2 tables. Results were adjusted for potential cofounders (age and family history) by logistic regression. All tests were two tailed at 5%. The R 2.5.0 software was used for all analysis.
results
The response rate for cases, controls and physicians was 88%, 76% and 100%, respectively. A total of 669 subjects (388 cases, 281 controls) were included in the study. Breakdown of case subjects is presented in Table 1 . The two groups were well balanced for age and family history of prostate cancer. The mean age (and standard deviation) for the case subjects was 67.2 (7.2) years and for the controls was 66.4 (9.1) years. Patients in the case group were diagnosed with prostate cancer between the ages of 46 and 84 [mean age 64.4 (7.0)]. There was no difference in the prevalence of alopecia or the incidence of prostate cancer in the father of cases and controls with early-onset alopecia (stage II-IV) ( Table 2) . Adjusted results are not presented because these were not significantly different.
hair loss and prostate cancer
Prevalence and pattern of hair loss by age for both case and control group subjects are presented in Table 3 . Data revealed that any balding present at age 20 (stage II-IV) was associated with an increased incidence of prostate cancer later in life. When compared with control group subjects, those with prostate cancer were twice as likely to have signs of alopecia at age 20 [odds ratio (OR) 2.01, P = 0.0285, 95% CI 1.07-3.79]). This trend was lost at ages 30 or 40.
pattern of hair loss and prostate cancer
In our population, the pattern of hair loss (frontal versus vertex versus both) was not a predictive factor for the development of cancer. There were a very low number of subjects with stage III and no subject with stage IV hair loss at age 20. (Table 4) .
discussion
For prostate cancer, recent publications have not been able to show an absolute benefit for screening in the general population [17, 18] . An improved knowledge of risk factors, especially those that are easily identifiable in the patient, may allow us to target a population at high risk of developing prostate cancer and that may benefit from screening or chemoprevention. While similar biological mechanisms seem to be involved in the development of both male pattern baldness and prostate cancer, no direct link has yet been identified. Androgens, however, seem to be implicated. Finasteride blocks the conversion of testosterone to dihydrotestosterone, the active metabolite of testosterone, slowing the progression of androgenic alopecia and decreasing the incidence of prostate cancer.
In this study, we have identified male pattern baldness arising at an early age, an easily identifiable and early-occurring trait, as a risk factor for developing prostate cancer. Data in the literature on the subject is, however, conflictual. Earlier studies failed to link male pattern baldness with prostate cancer, yet these evaluated balding status at the time of diagnosis of the prostate cancer [7, 8] . This is in contrast with more contemporary studies, which suggest that androgenic alopecia is associated with an increased, yet delayed, risk of prostate cancer. In a report by Hawk et al. [10] , based on a cohort of men followed prospectively for nearly 20 years, men with male pattern baldness at baseline had a greater incidence of prostate cancer (relative risk 1.5). In another study conducted at Duke University [9] , it was found that men who developed vertex baldness by age 30 had nearly a twofold increase in risk of developing prostate cancer. A more recent study, however, showed opposite results. Wright et al. [19] conducted a population-based case-control study where subjects recalled hair loss pattern at age 30 and at 1 year before diagnosis of prostate cancer using showcards. In this study, alopecia at age 30 had a 29% relative risk reduction for prostate cancer.
Our study, on the other hand, revealed that patients with prostate cancer were twice as likely to have androgenic alopecia at age 20. We were unable to find an association with the pattern of hair loss and the development of cancer. This may have been due to the very low prevalence of vertex (stage III) and combined frontal/vertex alopecia (stage IV) at the ages of 20 and 30 in our population. In addition, our study was not powered to detect a small difference between these groups. Finally, we did not detect a link between early-onset androgenic alopecia and an earlier age of diagnosis of prostate cancer or with the development of more aggressive prostate tumors. Possible limitations of our study include recall and selective recall bias; however, the retrospective self-reporting of male balding patterns has been validated [16, 17] and was used in other studies. Furthermore, we believe that because alopecia can impact self-perceptions [20] , most men would remember developing baldness, especially if it occurs at an early age. Another limitation of our study may be due to the fact that we did not control for other risk factors of prostate cancer such as African heritage or dietary differences; nevertheless, family history of prostate cancer was comparable in cases and controls.
conclusions Androgenic alopecia is a common disorder usually seen in older men, but it may arise precociously. Its link to prostate original article Annals of Oncology cancer is unclear and there is much disparity in the literature. While androgens may be implicated in both androgenic alopecia and prostate cancer, and the incidence of both increases with age, a direct relationship has yet to be proven. We encourage further work on the subject, whether molecular or genetic.
